Wave Life Sciences Ltd. announced that it has commenced an underwritten public offering of $175M in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. All of the securities in the offering will be sold by Wave Life Sciences. J.P. Morgan and Leerink Partners are acting as joint book-running managers for the offering. Truist Securities and Mizuho are acting as book-runners for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences price target raised to $20 from $16 at Leerink
- Deere dips after Trump tariff threat, DOJ to sue Visa: Morning Buzz
- Wave Life Sciences price target raised to $22 from $15 at H.C. Wainwright
- Wave Life Sciences Reports Promising Duchenne Therapy Trial Results
- Wave Life Sciences announces interim data fom ogoing Phase 2 FORWARD-53 study